BPC Stock Overview
Birzeit Pharmaceuticals Company manufactures and trades in various medicines in the Palestinian Authority.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Birzeit Pharmaceuticals Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.10 |
| 52 Week High | US$4.46 |
| 52 Week Low | US$3.90 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -3.53% |
| 1 Year Change | 0% |
| 3 Year Change | 60.78% |
| 5 Year Change | 68.97% |
| Change since IPO | 221.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| BPC | PS Pharmaceuticals | PS Market | |
|---|---|---|---|
| 7D | -1.9% | 1.0% | 0.4% |
| 1Y | 0% | 6.2% | -16.1% |
Return vs Industry: BPC underperformed the PS Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: BPC exceeded the PS Market which returned -16.1% over the past year.
Price Volatility
| BPC volatility | |
|---|---|
| BPC Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in PS Market | 5.9% |
| 10% least volatile stocks in PS Market | 2.2% |
Stable Share Price: BPC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BPC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | n/a | Talal Kadhim Nasereddin | bpc.ps |
Birzeit Pharmaceuticals Company manufactures and trades in various medicines in the Palestinian Authority. The company offers its products in various therapeutic fields comprising alimentary system, cardio-vascular system, muscolo-skeletal system, endocrines, central nervous system, genito-urinary system, obstetrics and gynecology, infections, dermatological preparations, ophthalmic drugs, respiratory system, and nutrition and metabolism, as well as ear, nose, and oropharynx. It also provides OTC products, such as multivitamins and minerals, and supplements; and skin/topical care, allergy and cold, eye care, mouth and nose care, pain and fever, and digestion and gastrointestinal products.
Birzeit Pharmaceuticals Company Fundamentals Summary
| BPC fundamental statistics | |
|---|---|
| Market cap | US$158.94m |
| Earnings (TTM) | US$6.12m |
| Revenue (TTM) | US$43.13m |
26.0x
P/E Ratio3.7x
P/S RatioIs BPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPC income statement (TTM) | |
|---|---|
| Revenue | US$43.13m |
| Cost of Revenue | US$28.16m |
| Gross Profit | US$14.97m |
| Other Expenses | US$8.85m |
| Earnings | US$6.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 34.71% |
| Net Profit Margin | 14.18% |
| Debt/Equity Ratio | 0% |
How did BPC perform over the long term?
See historical performance and comparison